Takeda’s Position on Falsified Medical Products

Summary

At Takeda, patient safety is our highest priority. To combat the growing trend of falsified medicines that deliberately misrepresent real medicines used to treat and prevent complex diseases, Takeda has a dedicated Global Product Protection team. This team employs a proactive and collaborative approach to identifying and mitigating the risks associated with falsified medical products. Takeda joins forces with law enforcement, regulatory authorities, industry organizations and other companies to fight the illegal operations behind falsified medical products.

Background

According to the World Health Organization, falsified medical products are those that deliberately misrepresent their identity, composition or source. They include counterfeit products, altered products, stolen products and illegally diverted products. Several factors contribute to the growing trends in falsified medical products, including criminals looking to make a financial gain, a lack of legislation and oversight, and a lack of coordination between relevant stakeholders.

Falsified medical products present significant threats to patients around the globe. They can undermine confidence in global health care systems and among health care professionals. They can also lead to treatment failure, harmful side effects and, in extreme cases, death.
Takeda recognizes that we have an important role to play in protecting the integrity of our products and is committed to being a reliable partner in the global fight against falsified medicines. Takeda’s dedicated Global Product Protection team collaborates with internal and external stakeholders to protect patients by fighting against falsified medical products.

Takeda’s Perspective

At Takeda, we are guided by our values of Takeda-ism brought to life through actions based on Patient-Trust-Reputation-Business, in that order. As such, we have a responsibility to safeguard the integrity of its products and support the global fight against falsified medicine. In doing so, we:

- Proactively partner with international and local law enforcement, regulatory agencies, other pharmaceutical companies and industry organizations to combat counterfeiting and illegal trading, while also educating patients, supply chain partners and customers on the dangers associated with these activities.

- Routinely set high security standards and requirements for supply chain partners worldwide, performing due diligence and audit against these requirements.

- Evaluate, develop and implement innovative anti-counterfeiting solutions for products and packaging to deter and detect counterfeiting, theft, diversion and tampering, (e.g., print security features, tamper evident security seals and serialization).

- Continuously detect, investigate, collect evidence of criminal organizations suspected of engaging in illegal trade of Takeda product(s). This includes active monitoring and disruption of illegal online pharmacies and other illicit internet trading.

Conclusion

Falsified medical products present a significant threat to global public health. Takeda is committed to safeguarding the integrity of its products and supporting the global fight against falsified medicine in order to protect patient safety, which is our highest priority. However, we recognize that this is not an issue we can tackle alone. In addition to addressing these challenges independently, we strive to form strong partnerships and promote innovative solutions to collaboratively protect our products and patient safety.
About Takeda

Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI), with expertise in immune and inflammatory diseases. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines.

May 2023

1 Source: Substandard and falsified medical products. Available at: https://www.who.int/news-room/fact-sheets/detail/substandard-and-falsified-medical-products